ClinicalTrials.gg
CompletedNCT01628926Updated May 23, 2014Results posted

A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients

A Phase 3 interventional study of SPM 962 and Ropinirole in Parkinson's Disease, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 8 sites in Japan. Open to participants aged 30 Years to 79 Years. Per ClinicalTrials.gov, last updated 2014-05-23.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
30 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.

Enrollment
3rd of 42
420 · median 123
Started
2009
with 1 other
Phase 3
20 of 44
none open now
Registered
23rd of 44
by date
Lead sponsor
7 of 44
Otsuka Pharmaceutical Co., Ltd.

Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 3rd largest by enrollment of the 42 interventional ones that give a count, is one of 2 that started in 2009, is one of 20 in phase 3, and was the 23rd registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing rotigotine in Parkinson Disease, or all of them as a file.
02

Study summary

  • To demonstrate the non-inferiority of SPM 962 to ropinirole in terms of efficacy in order to confirm clinical value of SPM 962.
  • To demonstrate the superiority of SPM 962 to placebo in terms of efficacy.
  • To investigate the tolerability and safety of SPM 962 up to 36.0 mg/day.
03

Conditions studied

  • Parkinson's Disease

Browse trials for

04

Who can participate

Ages eligible
30 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject diagnosed as having Parkinson's disease in accordance with "Diagnostic Criteria established by the Research Committee of MHLW-specified Intractable Neurodegenerative Diseases (1995)".
  • Subject is 30 and more and less than 80 years of age at the time of .
  • Hoehn \& Yahr stage 2-4 (on time).
  • Total UPDRS Part 3 score is over 10 at screening test (on time).
  • Subject is on a stable dose of L-dopa with no change in daily dose or dosing regimen for at least 28 days prior to the initial treatment of SPM 962.
  • Subject has any of the following problematic symptoms; 1) Wearing off phenomenon (including frozen gait at off time and dystonia at off time) 2) On and off phenomenon 3) Delayed-on and/or No-on phenomenon 4) Dyskinesia 5) Not well controlled with L-dopa.

Exclusion criteria

Exclusion Criteria:

  • Subject who has previously participated in a clinical trial of SPM962 and taken the product (IP).
  • Subject has psychiatric symptoms, e.g. confusion, hallucination, delusion, excitation, delirium, abnormal behavior at screening test or baseline.
  • Subject whose SBP declines by at least 30 mmHg from supine to standing position based on the orthostatic hypotension assessment, or subject who develops orthostatic hypotension at baseline.
  • Subject has a history of epilepsy, convulsion and other.
  • Subject who has complications or a history of serious cardiac diseases or arrhythmia (eg, congestive heart failure of class 3 or 4 in the classification, second or third degree atrioventricular block, complete left bundle branch block, sick sinus syndrome, ventricular fibrillation, myocardial infarction within 12 months prior to the screening test, or a complication of angina pectoris).
  • Subjects has -interval >450 msec twice at screening. Subject has a the average QTc-interval from two ECGs >450 msec in males and >470 msec in females at baseline.
  • Subject has congenital long QT syndrome.
  • Subject whose serum potassium level is \< 3.5mEq/L at the screening test.
  • Subject has a total >= 3.0 mg/dL or (GOT) or ALT(GPT) greater than 2.5 times of the upper limit of the reference range (or >= 100 IU/L) at screening test, or suffers complications of active phase of chronic hepatitis or liver cirrhosis.
  • Subject has BUN >= 30 mg/dL or serum creatinine >= 2.0 mg/dl at screening test.
  • Subject has a history of allergic reaction to topical agents such as transdermal patch.
  • Subject has a history of known intolerance/ to ropinirole and/or adverse drug reactions that prevent subject from receiving treatment.
  • Subject is pregnant or nursing or woman who plans pregnancy during the trial.
  • Subject is receiving therapy with prohibited drug specified in the study protocol.
  • Subject has a history of pallidotomy, thalamotomy, deep brain stimulation or fetal tissue transplant.
  • Subject has dementia, including DLB and PDD ( score \<= 24 at screening).
  • Subject who has a complication or history of malignant neoplastic disease, or received treatment for the disease within 12 months prior to the screening test.
  • Subject is unable to give consent.
  • Subject who is unable to properly record information in a diary.
  • Subject is participating in another trial of IPs or received other IPs within 12 weeks prior to commencement of study treatment.
  • Investigator judges that subject is inappropriate as a study subject with other reasons.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
420 participants (actual)

Study arms

  • Experimental
    SPM 962

    SPM 962 transdermal patch

    Drug: SPM 962

  • Active comparator
    Ropinirole

    Ropinirole tablet

    Drug: Ropinirole

  • Placebo comparator
    Placebo

    SPM962 placebo patch and Ropinirole placebo tab

    Drug: Placebo

Interventions

  • SPM 962 transdermal patch once a daily up to 36.0 mg/day

  • Ropinirole oral administration TID up to 15.0 mg/day

  • DrugPlacebo

    SPM962-placebo patch and Ropinirole-placebo tab

06

What researchers measure

Primary outcomes

  1. Unified Parkinson's Disease Rating Score (UPDRS) Part 3 Sum Score

    Mean change (LOCF) from baseline in UPDRS Part 3 sum score (on state) at 16 weeks after dosing. UPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

    Time frame: baseline, 16 weeks after dosing

Secondary outcomes

  1. UPDRS Part 3 Sum Score

    Mean change (LOCF) from baseline in UPDRS Part 3 sum score (on state) at 8 and 10 weeks after dosing. UPDRS Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

    Time frame: baseline, 8 and 10 weeks after dosing

  2. UPDRS Part 2 Sum Score

    Mean change (LOCF) from baseline in UPDRS Part 2 sum score (average scores of on state and off state) at 16 weeks after dosing. UPDRS 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

    Time frame: Baseline, 16 weeks after dosing

  3. Off Time

    Mean change (LOCF) from baseline in off time at 16 weeks after dosing. Off-time is a state where L-Dopa becomes ineffective. Off-time was measured by patient diary in hours/day.

    Time frame: Baseline, 16 weeks after dosing

  4. Parkinson's Disease Sleep Scale-2 (PDSS-2)

    Mean change (LOCF) from baseline in PDSS-2 sum score at 16 weeks after dosing. PDSS-2 is a scale for assessing sleep disorders in Parkinson's disease. PDSS consists of 15 questions about sleep and nocturnal disturbances. The score of each question ranges from 0 (never) to 4 (very frequent). The sum of each question serves as the scale score. Thus a decrease in the scores means improvement.

    Time frame: Baseline, 16 weeks after dosing

  5. On Time

    Mean change (LOCF) from baseline in on time at 16 weeks after dosing. On-time is a state where L-Dopa is effective. On-time was measured by patient diary in hours/day.

    Time frame: Baseline, 16 weeks after dosing

  6. On Time Without Dyskinesia Disturbing Daily Activities

    Mean change (LOCF) from baseline in on time without dyskinesia disturbing daily activities at 16 weeks after dosing. On-time is a state where L-Dopa is effective. On-time was measured by patient diary in hours/day.

    Time frame: Baseline, 16 weeks after dosing

  7. On Time With Dyskinesia Disturbing Daily Activities

    Mean change (LOCF) from baseline in on time with dyskinesia disturbing daily activities at 16 weeks after dosing (rate against on time).

    Time frame: Baseline, 16 weeks after dosing

  8. Effective Rate in UPDRS Part 3 Sum Score

    Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 3 sum score (on state) at 16 weeks after dosing.

    Time frame: Baseline, 16 weeks after dosing

  9. Effective Rate in UPDRS Part 2 Sum Score

    Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 2 sum score (average scores of on state and off state) at 16 weeks after dosing.

    Time frame: Baseline, 16 weeks after dosing

  10. Effective Rate in Off Time

    Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in off time at 16 weeks after dosing. On-time is a state where L-Dopa is effective. On-time was measured by patient diary in hours/day.

    Time frame: Baseline, 16 weeks after dosing

  11. Clinical Global Impression (CGI)

    Change (LOCF) from baseline in CGI score. CGI improvement is a clinician-reported scale for assessing how much the patient's illness has improved or worsened from baseline. The scale scoring criteria are 1: very much improved, 2: much improved, 3: minimally improved, 4: no change, 5: minimally worse, 6: much worse, 7: very much worse. A decrease in the scores means improvement.

    Time frame: Baseline, 16 weeks after dosing

  12. Dystonia (at an Early Hour)

    Change (LOCF) from baseline in occurrence of Dystonia (at an early hour).

    Time frame: Baseline, 16 weeks after dosing

  13. Dystonia (in the Daytime)

    Change (LOCF) from baseline in occurrence of Dystonia (in the daytime).

    Time frame: Baseline, 16 weeks after dosing

07

Results

Posted May 23, 2014

Participant flow

Participant flow — Overall Study
MilestoneSPM 962RopinirolePlacebo
Started16816785
Completed14214468
Not completed262317
Withdrew: Adverse event13119
Withdrew: Lack of efficacy215
Withdrew: Withdrawal by subject642
Withdrew: Protocol violation010
Withdrew: Discontinuation criteria340
Withdrew: Physician decision221

Outcome measures

PrimaryUnified Parkinson's Disease Rating Score (UPDRS) Part 3 Sum Score

Mean change (LOCF) from baseline in UPDRS Part 3 sum score (on state) at 16 weeks after dosing. UPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

Time frame:
baseline, 16 weeks after dosing
Reported as:
Mean · Scores on a scale
Unified Parkinson's Disease Rating Score (UPDRS) Part 3 Sum Score
Scores on a scaleSPM 962RopinirolePlacebo
Unified Parkinson's Disease Rating Score (UPDRS) Part 3 Sum Score-10.9 ± 8.1-9.5 ± 8.7-4.5 ± 9.7
SecondaryUPDRS Part 3 Sum Score

Mean change (LOCF) from baseline in UPDRS Part 3 sum score (on state) at 8 and 10 weeks after dosing. UPDRS Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

Time frame:
baseline, 8 and 10 weeks after dosing
Reported as:
Mean · Scores on a scale
UPDRS Part 3 Sum Score
Scores on a scaleSPM 962RopinirolePlacebo
8 weeks after dosing-9.7 ± 7.2-8.4 ± 8.1-5.5 ± 8.3
10 weeks after dosing-9.9 ± 7.1-8.8 ± 8.3-5.3 ± 9.0
SecondaryUPDRS Part 2 Sum Score

Mean change (LOCF) from baseline in UPDRS Part 2 sum score (average scores of on state and off state) at 16 weeks after dosing. UPDRS 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

Time frame:
Baseline, 16 weeks after dosing
Reported as:
Mean · Scores on a scale
UPDRS Part 2 Sum Score
Scores on a scaleSPM 962RopinirolePlacebo
UPDRS Part 2 Sum Score-3.6 ± 4.1-2.9 ± 3.5-1.3 ± 3.4
SecondaryOff Time

Mean change (LOCF) from baseline in off time at 16 weeks after dosing. Off-time is a state where L-Dopa becomes ineffective. Off-time was measured by patient diary in hours/day.

Time frame:
Baseline, 16 weeks after dosing
Reported as:
Mean · Hours/day
Off Time
Hours/daySPM 962RopinirolePlacebo
Off Time-1.3 ± 2.9-2.0 ± 3.0-0.4 ± 2.7
SecondaryParkinson's Disease Sleep Scale-2 (PDSS-2)

Mean change (LOCF) from baseline in PDSS-2 sum score at 16 weeks after dosing. PDSS-2 is a scale for assessing sleep disorders in Parkinson's disease. PDSS consists of 15 questions about sleep and nocturnal disturbances. The score of each question ranges from 0 (never) to 4 (very frequent). The sum of each question serves as the scale score. Thus a decrease in the scores means improvement.

Time frame:
Baseline, 16 weeks after dosing
Reported as:
Mean · Scores on a scale
Parkinson's Disease Sleep Scale-2 (PDSS-2)
Scores on a scaleSPM 962RopinirolePlacebo
Parkinson's Disease Sleep Scale-2 (PDSS-2)-3.1 ± 6.8-3.4 ± 7.6-1.8 ± 7.0
SecondaryOn Time

Mean change (LOCF) from baseline in on time at 16 weeks after dosing. On-time is a state where L-Dopa is effective. On-time was measured by patient diary in hours/day.

Time frame:
Baseline, 16 weeks after dosing
Reported as:
Mean · Hours/day
On Time
Hours/daySPM 962RopinirolePlacebo
On Time1.3 ± 2.71.7 ± 2.90.2 ± 2.6
SecondaryOn Time Without Dyskinesia Disturbing Daily Activities

Mean change (LOCF) from baseline in on time without dyskinesia disturbing daily activities at 16 weeks after dosing. On-time is a state where L-Dopa is effective. On-time was measured by patient diary in hours/day.

Time frame:
Baseline, 16 weeks after dosing
Reported as:
Mean · Hours/day
On Time Without Dyskinesia Disturbing Daily Activities
Hours/daySPM 962RopinirolePlacebo
On Time Without Dyskinesia Disturbing Daily Activities1.1 ± 2.91.6 ± 3.00.3 ± 2.6
SecondaryOn Time With Dyskinesia Disturbing Daily Activities

Mean change (LOCF) from baseline in on time with dyskinesia disturbing daily activities at 16 weeks after dosing (rate against on time).

Time frame:
Baseline, 16 weeks after dosing
Reported as:
Mean · Hours
On Time With Dyskinesia Disturbing Daily Activities
HoursSPM 962RopinirolePlacebo
On Time With Dyskinesia Disturbing Daily Activities1.3 ± 11.00.6 ± 7.8-0.2 ± 1.4
SecondaryEffective Rate in UPDRS Part 3 Sum Score

Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 3 sum score (on state) at 16 weeks after dosing.

Time frame:
Baseline, 16 weeks after dosing
Reported as:
Number · Percentage of participants
Effective Rate in UPDRS Part 3 Sum Score
Percentage of participantsSPM 962RopinirolePlacebo
≥20% decrease80.5 (74.4 to 86.6)69.1 (62.0 to 76.1)56.6 (46.0 to 67.3)
≥30% decrease69.5 (62.5 to 76.6)60.6 (53.2 to 68.1)39.8 (29.2 to 50.3)
SecondaryEffective Rate in UPDRS Part 2 Sum Score

Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 2 sum score (average scores of on state and off state) at 16 weeks after dosing.

Time frame:
Baseline, 16 weeks after dosing
Reported as:
Number · Percentage of participants
Effective Rate in UPDRS Part 2 Sum Score
Percentage of participantsSPM 962RopinirolePlacebo
≥20% decrease65.2 (57.9 to 72.6)56.7 (49.1 to 64.3)47.0 (36.3 to 57.7)
≥30% decrease55.9 (48.2 to 63.6)43.3 (35.7 to 50.9)28.9 (19.2 to 38.7)
SecondaryEffective Rate in Off Time

Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in off time at 16 weeks after dosing. On-time is a state where L-Dopa is effective. On-time was measured by patient diary in hours/day.

Time frame:
Baseline, 16 weeks after dosing
Reported as:
Number · Percentage of participants
Effective Rate in Off Time
Percentage of participantsSPM 962RopinirolePlacebo
≥20% decrease61.8 (52.7 to 70.9)65.5 (56.7 to 74.3)47.4 (34.4 to 60.3)
≥30% decrease55.5 (46.2 to 64.7)61.9 (53.0 to 70.9)40.4 (27.6 to 53.1)
SecondaryClinical Global Impression (CGI)

Change (LOCF) from baseline in CGI score. CGI improvement is a clinician-reported scale for assessing how much the patient's illness has improved or worsened from baseline. The scale scoring criteria are 1: very much improved, 2: much improved, 3: minimally improved, 4: no change, 5: minimally worse, 6: much worse, 7: very much worse. A decrease in the scores means improvement.

Time frame:
Baseline, 16 weeks after dosing
Reported as:
Number · Percentage of Participants
Clinical Global Impression (CGI)
Percentage of ParticipantsSPM 962RopinirolePlacebo
Decreased50.349.130.9
Decreased (by at least 2 points)8.08.53.7
Increased3.14.24.9
Increased (by at least 2 points)000
SecondaryDystonia (at an Early Hour)

Change (LOCF) from baseline in occurrence of Dystonia (at an early hour).

Time frame:
Baseline, 16 weeks after dosing
Reported as:
Number · Percentage of participants
Dystonia (at an Early Hour)
Percentage of participantsSPM 962RopinirolePlacebo
Decreased10.410.97.4
Decreased (by at least 2 events)1.84.22.5
Increased1.23.03.7
Increased (by at least 2 events)00.60
SecondaryDystonia (in the Daytime)

Change (LOCF) from baseline in occurrence of Dystonia (in the daytime).

Time frame:
Baseline, 16 weeks after dosing
Reported as:
Number · Percentage of Participants
Dystonia (in the Daytime)
Percentage of ParticipantsSPM 962RopinirolePlacebo
Decreased8.67.93.7
Decreased (by at least 2 events)3.75.52.5
Increased3.72.44.9
Increased (by at least 2 events)1.80.61.2

Adverse events

Collected over 21 weeks. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SPM 962—7/168 (4.2%)140/168 (83.3%)
Ropinirole—5/167 (3%)99/167 (59.3%)
Placebo—6/85 (7.1%)40/85 (47.1%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventSPM 962RopinirolePlacebo
Angina PectorisCardiac disorders0/1680/1671/85
PneumoniaInfections and infestations0/1680/1671/85
Urinary Tract InfectionInfections and infestations0/1680/1671/85
Spinal Compression FractureInjury, poisoning and procedural complications1/1680/1671/85
Carcinoma GastricNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1680/1671/85
Disease Parkinson'sNervous system disorders1/1681/1671/85
Cerebral Artery EmbolismNervous system disorders0/1680/1671/85
Embolism PulmonaryRespiratory, thoracic and mediastinal disorders0/1680/1671/85
Gastric Ulcer BleedingGastrointestinal disorders0/1681/1670/85
CholecystitisHepatobiliary disorders0/1681/1670/85
Most frequent other events
Showing 10 of 16
Most frequent other events
EventSPM 962RopinirolePlacebo
Application Site ReactionGeneral disorders91/16830/16710/85
NasopharyngitisInfections and infestations28/16824/16713/85
DyskinesiaNervous system disorders27/16823/1671/85
NauseaGastrointestinal disorders25/16823/1677/85
Hallucination VisualPsychiatric disorders13/16810/1673/85
ContusionInjury, poisoning and procedural complications7/1682/1676/85
VomitingGastrointestinal disorders11/16811/1672/85
SomnolencePsychiatric disorders11/1689/1672/85
CystitisInfections and infestations3/1683/1674/85
Orthostatic HypotensionVascular disorders5/1687/1674/85

Baseline characteristics

6 subjects were excluded. Met the exclusion criteria: 2 of SPM962, 1 of ropinirole Lack of efficacy observation: 2 of SPM962, 1 of Placebo

Age, Categorical
Age, Categorical(Participants)SPM 962RopinirolePlaceboTotal
<=18 years0000
Between 18 and 65 years715228151
>=65 years9311456263
Age, Continuous
Age, Continuous(years)SPM 962RopinirolePlaceboTotal
Mean64.8 ± 8.867.0 ± 7.965.3 ± 7.965.8 ± 8.3
Sex: Female, Male
Sex: Female, Male(Participants)SPM 962RopinirolePlaceboTotal
Female1039842243
Male616842171
Region of Enrollment
Region of Enrollment(participants)SPM 962RopinirolePlaceboTotal
Japan16416684414
08

Study locations

8 sites
  • Chubu Region, Japan
  • Chugoku Region, Japan
  • Hokkaido Region, Japan
  • Kanto Region, Japan
  • Kinki Region, Japan
  • Kyushu Region, Japan
  • Shikoku Region, Japan
  • Tohoku Region, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2009, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2012
First posted
Jun 27, 2012
Start
Jun 2009
Primary completionActual
May 2011
CompletionActual
May 2011
Results first posted
May 23, 2014
Last update
May 23, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01628926
Responsible party
Sponsor
First posted
Jun 27, 2012
Start date
Jun 2009
Primary completion
May 2011
Completion
May 2011
Results posted
May 23, 2014
Last update
May 23, 2014

Study contacts

Kyoji Imaoka, Mr
study director · Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion